| Start | End | Session | Location |
|---|---|---|---|
| 09:00 | 10:20 | Saga Hall | |
| Moderators: | Hans-Gustaf Ljunggren, Karolinska Institutet | ||
| Katy Rezvani, MD Anderson Cancer Center | |||
| 09:00 | |||
| Todd Fehniger, Washington University School of Medicine | |||
| Memory-like NK cell biology and cancer immunotherapy | |||
| 09:20 | |||
| Katy Rezvani, MD Anderson Cancer Center | |||
| State of off-the-shelf cellular therapies in the clinic: Engineering NK cells for cancer immunotherapy | |||
| 09:40 | |||
| Dean Lee, Nationwide Children's Hospital | |||
| Implementation of universal donor sourcing for NK cell clinical trials | |||
| 10:00 | |||
| Jeffrey Miller, University of Minnesota | |||
| To be announced | |||
| 10:20 | 11:00 | Coffee Break | Foyer |
| 11:00 | 12:00 | Saga Hall | |
| Moderators: | Aharon Freud, The Ohio State University | ||
| Ebba Sohlberg, Karolinska Institutet | |||
| 11:00 | |||
| Salim Khakoo, University of Southampton | |||
| Exportin-1 (XPO-1) as a target for natural killer cells in hepatocellular carcinoma | |||
| 11:10 | |||
| Michal Sheffer, Dana-Farber Cancer Institute | |||
| Cellular therapy of cytokine induced memory-like NK cells for the treatment of head and neck cancer | |||
| 11:20 | |||
| Erin Jeremy, The Ohio State University | |||
| The role of persistent AP-1 activation in NK cell exhaustion programming in AML | |||
| 11:30 | |||
| Sunil Acharya, MD Anderson Cancer Center | |||
| Generation and screening of various CD70 CAR NK cells identify the most effective construct against hematologic malignancies | |||
| 11:40 | |||
| Veronika Bachanova, University Of Minnesota | |||
| Allogeneic NK Cell Therapy for Lymphoma Revealed Cross-Talk with Adaptive T-Cell Immunity: Insights from Tumor Microenvironment Spatial Analysis | |||
| 11:50 | |||
| Jiri Eitler, Technische Universität Dresden | |||
| Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss | |||
| 12:00 | 13:30 | Lunch (Hosted by NextGenNK) | Restaurant |
| 13:30 | 14:30 | Saga Hall | |
| Moderators: | Rizwan Romee, Dana-Farber Cancer Institute | ||
| Veronika Bachanova, University of Minnesota | |||
| 13:30 | |||
| Dan Kaufman, University of California San Diego | |||
| Development of drug resistant NK cells for improved anti-tumor activity | |||
| 13:50 | |||
| Ulrike Kohl, Fraunhofer Institut für Zelltherapie und Immunologie (IZI) | |||
| From CAR T to CAR NK cells: Pushing the boundaries in cancer treatment and beyond | |||
| 14:10 | |||
| Erik Vivier, Centre d’Immunologie de Marseille-Luminy (CIML) | |||
| Harnessing NK cell immunity in cancer therapies | |||
| 14:30 | 15:15 | Saga Hall | |
| Moderators: | Rizwan Romee, Dana-Farber Cancer Institute | ||
| Evren Alici, Karolinska Institutet | |||
| Sarah Cooley, Sanofi | |||
| 15:15 | 16:00 | Closing of Workshop. Coffee and refreshments | Foyer |
| 16:00 | 17:00 | Saga Hall | |
| 16:00 | |||
| Karl-Johan Malmberg, University of Oslo | |||
| Welcome to NK2023! | |||
| 16:10 | |||
| Lewis Lanier, University of California San Francisco | |||
| Natural Killer cells – a 4-decade Quest | |||
| 17:00 | 17:30 | Saga Hall | |
| Moderators: | Erik Dissen, University of Oslo | ||
| Jakob Michaelsson, Karolinska Institutet | |||
| 17:00 | |||
| Olli Dufva, University of Helsinki | |||
| Single-cell functional genomics of natural killer cell evasion in blood cancers | |||
| 17:05 | |||
| Arman Bashirova, Leidos Biomedical Research | |||
| HLA class I signal peptide polymorphism: impact on HLA-E-mediated regulation of NK and T cells | |||
| 17:10 | |||
| Sytse Piersma, Washington University in St Louis | |||
| HuR-dependent NK cell expansion mediate control of primary tumors without affecting clearance of tumor metastases. | |||
| 17:15 | |||
| Linnea Kristen, University of Gothenburg | |||
| Deletion of the TMEM30A gene allows leukemic cell evasion of NK cell cytotoxicity | |||
| 17:20 | |||
| Tobias Bexte, University Hospital Frankfurt | |||
| CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-directed CAR-NK cells | |||
| 17:25 | |||
| May Daher, MD Anderson Cancer Center | |||
| Crosstalk between NK cells and myeloid blasts leads to an epigenetic state of exhaustion | |||
| 18:00 | 19:30 | Reception | Restaurant |
| 19:30 | 21:00 | Poster Session 1, A001-A130 | Poster Area |
